168 related articles for article (PubMed ID: 22241682)
1. Effect of dual inhibition of apoptosis and autophagy in prostate cancer.
Saleem A; Dvorzhinski D; Santanam U; Mathew R; Bray K; Stein M; White E; DiPaola RS
Prostate; 2012 Sep; 72(12):1374-81. PubMed ID: 22241682
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
[TBL] [Abstract][Full Text] [Related]
3. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.
Kim KW; Moretti L; Mitchell LR; Jung DK; Lu B
Clin Cancer Res; 2009 Oct; 15(19):6096-105. PubMed ID: 19773376
[TBL] [Abstract][Full Text] [Related]
4. Bcl-2 modulation to activate apoptosis in prostate cancer.
Bray K; Chen HY; Karp CM; May M; Ganesan S; Karantza-Wadsworth V; DiPaola RS; White E
Mol Cancer Res; 2009 Sep; 7(9):1487-96. PubMed ID: 19737977
[TBL] [Abstract][Full Text] [Related]
5. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
6. Bcl2L12 with a BH3-like domain in regulating apoptosis and TMZ-induced autophagy: a prospective combination of ABT-737 and TMZ for treating glioma.
Yang MC; Loh JK; Li YY; Huang WS; Chou CH; Cheng JT; Wang YT; Lieu AS; Howng SL; Hong YR; Chou AK
Int J Oncol; 2015 Mar; 46(3):1304-16. PubMed ID: 25586056
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
Fang H; Harned TM; Kalous O; Maldonado V; DeClerck YA; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(22):7093-104. PubMed ID: 21933888
[TBL] [Abstract][Full Text] [Related]
8. B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells.
Yao X; Li X; Zhang D; Xie Y; Sun B; Li H; Sun L; Zhang X
Tumour Biol; 2017 Mar; 39(3):1010428317695965. PubMed ID: 28351336
[TBL] [Abstract][Full Text] [Related]
9. Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
Noll T; Schultze-Seemann S; Kuckuck I; Michalska M; Wolf P
Cancer Immunol Immunother; 2018 Mar; 67(3):413-422. PubMed ID: 29188305
[TBL] [Abstract][Full Text] [Related]
10. Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer.
Zinn RL; Gardner EE; Dobromilskaya I; Murphy S; Marchionni L; Hann CL; Rudin CM
Mol Cancer; 2013 Mar; 12():16. PubMed ID: 23452820
[TBL] [Abstract][Full Text] [Related]
11. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
[TBL] [Abstract][Full Text] [Related]
12. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells.
Huang S; Sinicrope FA
Autophagy; 2010 Feb; 6(2):256-69. PubMed ID: 20104024
[TBL] [Abstract][Full Text] [Related]
14. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
15. HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway.
Ni Z; Wang B; Dai X; Ding W; Yang T; Li X; Lewin S; Xu L; Lian J; He F
Free Radic Biol Med; 2014 May; 70():194-203. PubMed ID: 24576507
[TBL] [Abstract][Full Text] [Related]
16. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
17. Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines.
Avsar Abdik E; Abdik H; Turan D; Sahin F; Berger MR; Kaleagasioglu F
Mol Biol Rep; 2021 Dec; 48(12):7755-7765. PubMed ID: 34647221
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
19. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
